Lilly breaks ground in Houston, one of ten U.S. manufacturing sites announced since 2020
Why now
Thesis: Domestic API manufacturing cuts tariff and supply-chain exposure
Catalyst to watch: Obesity drug pipeline milestones or approvals
Main risk: Manufacturing execution or cost overruns
Why it matters
Domestic API manufacturing reduces tariff and supply-chain exposure for Lilly's obesity drug pipeline.
Details
New facility will manufacture active pharmaceutical ingredients for medicines like Foundayo (orforglipron), strengthening domestic supply chain Site will employ more than 600 people in high-wage jobs $12.5 million in support to build talent pipeline, workforce training center with San...
Sources
- prnewswire · 2026-09-21 21:40 UTC